The promise and limitations of anti-inflammatory agents for the treatment of major depressive disorder

Research output: Chapter in Book/Report/Conference proceedingChapter

11 Scopus citations

Abstract

This review provides a critical perspective on recent meta-analyses suggesting that several anti-inflammatory modalities, including nonsteroidal anti inflammatory drugs (NSAIDs), omega-3 fatty acids, and cytokine antagonist, possess generalizable antidepressant properties. By examining confounds and limitations in the available literature it is suggested that current data suggest that only a sub-group of individuals with major depressive disorder (MDD) have evidence of increased inflammatory biomarkers and it is in these individuals that anti inflammatory agents show promise for reducing depressive symptoms. The treatment implications of this cautionary perspective are discussed.

Original languageEnglish (US)
Title of host publicationCurrent Topics in Behavioral Neurosciences
PublisherSpringer Verlag
Pages287-302
Number of pages16
Volume31
DOIs
Publication statusPublished - 2017
Externally publishedYes

Publication series

NameCurrent Topics in Behavioral Neurosciences
Volume31
ISSN (Print)1866-3370
ISSN (Electronic)1866-3389

    Fingerprint

Keywords

  • Antidepressants
  • Cytokine antagonists
  • Cytokines
  • Inflammation
  • Major depressive disorder
  • Nonsteroidal anti-inflammatory drugs
  • Omega-3 fatty acids

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience

Cite this

Raison, C. L. (2017). The promise and limitations of anti-inflammatory agents for the treatment of major depressive disorder. In Current Topics in Behavioral Neurosciences (Vol. 31, pp. 287-302). (Current Topics in Behavioral Neurosciences; Vol. 31). Springer Verlag. https://doi.org/10.1007/7854_2016_26